canada clinical guidance

Progestogen-only pill (POP): traditional, desogestrel, drospirenone

A Canadian clinical summary of progestogen-only pill (pop): traditional, desogestrel, drospirenone, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian Contraception Consensus (Part 3 of 4), Chapter 8: Progestin-Only Contraception. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC progestin contraception

Source-attributed clinical priorities

  • Confirm pregnancy status and review breast cancer, liver disease, interacting medicines, bleeding concerns and adherence needs.
  • Explain that missed-pill windows and backup instructions differ by progestogen product.
  • Plan follow-up for troublesome bleeding, adverse effects or adherence and give emergency-contraception advice after incorrect use.
  • Different progestogen-only pills have different missed-pill windows, so advice must match the exact product.
sources for this section:SOGC progestin contraception

Practical assessment and management workflow

1
Exclude pregnancy and review breast cancer, liver disease, unexplained bleeding and interacting medicines.
2
Discuss bleeding variability, daily timing, effectiveness and alternatives including longer-acting methods.
3
Explain product-specific start, backup and missed-dose instructions.
4
Review adherence, bleeding, pregnancy symptoms and any new contraindication.
sources for this section:SOGC progestin contraception

Safety, red flags and urgent escalation

  • Severe abdominal pain with a positive pregnancy test requires ectopic assessment.
  • Enzyme-inducing medicines may reduce effectiveness of some oral progestogen methods.
  • Do not apply missed-pill instructions from one formulation to another.
sources for this section:SOGC progestin contraception

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC progestin contraception

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC progestin contraception

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Society of Obstetricians and Gynaecologists of CanadaCanadian Contraception Consensus (Part 3 of 4), Chapter 8: Progestin-Only Contraceptionaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.